Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recruitment considerations only and not because of safety or outcomes issues
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Rhode Island Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A non-interventional, prospective observational study to assess the performance of SeptiCyteĀ® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS
This study is evaluating a molecular diagnostic device developed to distinguish between sepsis and infection-negative SIRS among critically ill patients.
This study is a prospective, non-randomized, non-interventional, observational trial of patients with suspected sepsis in the medical and/or surgical wards. The study is being conducted on two preselected patient care units.
All patients identified by a local screening tool undergo physician review. If the suspicion of sepsis is found to be plausible, routine and conventional diagnostic procedures, including: routine bloods, blood culture and specialized tests are conducted.
Blood collection for SeptiCyteĀ® Lab and SeptIDĀ® is drawn within 6 hours of a positive screen - both use peripheral blood as the clinical sample. The diagnostic performance of the two experimental assays will be compared to Retrospective Physician Diagnosis (RPD), and conventional microbiological culture. The results of SeptiCyteĀ® Lab and SeptIDĀ® are not used in any clinical decision-making.
This data will be used to analyze the performance of SeptiCyteĀ® Lab according to the endpoint measures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SeptiCyte Lab molecular diagnostic test (non-interventional) | Other | This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response. |
| Measure | Description | Time Frame |
|---|---|---|
| SeptiCyteĀ® Lab test result versus Retrospective Physician Diagnosis (RPD) result | To validate the ability of the SeptiCyteĀ® Lab test to correctly discriminate infection positive from infection negative SIRS in hospital ward patients with two or more SIRS criteria compared to the non-reference method of retrospective physician diagnosis (RPD). | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| SeptiCyteĀ® Lab test result versus test results for other sepsis biomarkes, including leukocytosis, bandemia, & procalcitonin | To compare SeptiCyteĀ® Lab test scores with other clinical sepsis biomarkers to assess its ability to discriminate infection positive from infection negative SIRS. | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| SeptiCyteĀ® Lab test result versus a generalized sepsis screening protocol for identifying potential cases of sepsis | To compare true positive rates of sepsis diagnosis in patients identified only by the RISE2 screening protocol vs. RISE2 screening protocol plus SeptiCyteĀ® Lab results on Day 1. | 1 day |
| SeptIDĀ® test result versus microbiological reference methods for identifying pathogen(s) |
Inclusion Criteria:
18-89 years old on the day of enrollment.
Currently admitted to study designated medical or surgical ward
Have a clinical suspicion of sepsis as determined by two physicians after identification by hospital screening tool.
Screened positive for sepsis, severe sepsis or septic shock using the RISE2 screening tool.
Completed SBAR handover (Situation, Background, Assessment, Recommendation)
SIRS present as defined by the presence of two or more of the following:
Exclusion Criteria:
Not provided
Not provided
Adults aged 18 years or older, previously admitted to medical and/or surgical general hospital wards, who are suspected of sepsis as identified by an in-hospital early-warning screening tool.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mitchell Levy, MD | Rhode Island Hospital | Principal Investigator |
| Steven Opal, MD | Memorial Hospital of Rhode Island | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rhode Island Hospital | Providence | Rhode Island | 02903 | United States |
Not provided
| Label | URL |
|---|---|
| Sponsor's website | View source |
Not provided
There is no plan to make individual participant data available.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood and plasma specimens for nucleic acid and protein analysis
To assess the performance of the SeptIDĀ® test against microbiological reference methods for identifying the a pathogen via blood culture. |
| 7 days |
| D013568 |
| Pathological Conditions, Signs and Symptoms |